Liver News and Research

RSS

Short bursts of vigorous activity can lower risk of major diseases

People who get just a few minutes of vigorous activity daily are less likely to develop eight major diseases, including arthritis, heart disease and dementia, according to research published in the European Heart Journal today (Monday).

29 Mar 2026

Minimally invasive valve repair lowers hospitalizations in heart failure patients

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received optimal medical therapy plus a minimally invasive procedure using a clip to repair the valve were significantly less likely to die, have a heart attack or stroke and 40% less likely to be hospitalized for heart failure compared with similar patients who were randomly assigned to optimal medical therapy alone.

29 Mar 2026

Higher sugar intake raises gallstone risk in adults, study finds

A cross-sectional NHANES study of 8,975 U.S. adults found that higher total dietary sugar intake was associated with higher odds of gallstones, with each 100 g/day increase linked to a 41% rise after full adjustment. The findings suggest sugar intake may be a modifiable gallstone risk factor, but the study relied on self-reported gallstones and cannot establish causation.

29 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Ultrasound advances offer noninvasive assessment of portal hypertension severity

Portal hypertension (PH), a serious complication of liver cirrhosis, is defined as a pressure gradient > 5 mmHg between the portal vein and the inferior vena cava.

27 Mar 2026

Molecular test shows high sensitivity in detecting bile duct cancer

When patients develop a narrowing or blockage in the bile ducts – the tubes connecting the liver, gallbladder and intestines – physicians must determine whether the cause is cancer or a benign condition.

27 Mar 2026

Machine learning model can predict 28-day mortality in sepsis patients

Sepsis is one of the most common and lethal syndromes encountered in intensive care units (ICUs), and acute respiratory failure (ARF) represents one of its most critical complications.

27 Mar 2026

New tool identifies harmful nutrition misinformation and evaluates potential risk

A new tool that not only identifies diet and nutrition misinformation online but also evaluates the content's risk for potential harm has been developed by a team of UCL researchers.

27 Mar 2026

Do multi-strain probiotics improve long covid symptoms?

Multi-strain probiotics show potential to modulate gut microbiome in long COVID, yet their impact on inflammation and recovery is not statistically significant.

27 Mar 2026

Machine learning model predicts liver cancer risk with high accuracy

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high accuracy.

26 Mar 2026

New algorithm enables precise subtyping of metabolic liver disease

Metabolic-associated steatotic liver disease (MASLD) is a clinically heterogeneous condition with highly variable outcomes affecting more than 30% individuals globally.

26 Mar 2026

Obesity-driven organ enlargement may boost cancer risk

Scientists at City of Hope® and TGen (part of City of Hope) are the first to explain a major mechanism for why gaining excess weight increases your risk of cancer.

26 Mar 2026

Lower hemoglobin levels within the normal range linked to better metabolic health

Finnish researchers found that hemoglobin levels that are within the normal range but at the lower end may be beneficial for health, particularly for glucose metabolism and cardiovascular health.

25 Mar 2026

iXCells Biotechnologies joins international collaboration to evaluate chemotherapeutic toxicity in human organoids

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced it has entered an international collaboration with Rosebud Biosciences ("Rosebud"), Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids.

From iXCells Biotechnologies 25 Mar 2026

Redesigned lipid nanoparticles improve mRNA delivery to lymph nodes

Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to steer the particles toward lymph nodes while reducing off-target delivery to the liver.

24 Mar 2026

Gut microbes drive fat browning in response to diet

White adipose tissue stores energy, while brown and beige fat burn energy through thermogenesis. Under certain environmental conditions, white fat can transition into beige fat in a process known as browning.

24 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

Early obesity treatment reduces long-term health risks for all children

Children living with obesity but showing no signs of metabolic complications still have a significantly increased risk of developing type 2 diabetes, high blood pressure, and abnormal blood lipid levels later in life.

23 Mar 2026

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease over five years. The study also found no increased risk of hospitalization for diabetic ketoacidosis or severe hypoglycemia, supporting further randomized trials of GLP-1RAs as adjunctive therapy in type 1 diabetes.

22 Mar 2026